Rare Disease Drug Govorestat & Odevixibat Resubmission Among New EU Filings

 
• By Neena Brizmohun

The latest marketing applications under review by the European Medicines Agency include govorestat for classic galactosemia, a condition for which there are no treatments, and odevixibat for Alagille syndrome.

EU marketing applications for a new batch of drugs are under review • Source: Shutterstock

More from Europe

More from Geography